Renal Anemia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

 Renal Anemia Market Outlook

Thelansis’s “Renal Anemia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Renal Anemia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Renal Anemia Overview

Anemia frequently develops as a chronic kidney disease (CKD) complication, reducing patient quality of life. It increases morbidity and mortality and hastens the progression of CKD. In the context of CKD patients, anemia is characterized by hemoglobin (Hb) levels falling below two times the standard deviation of mean Hb in the general population, adjusted for age and gender. The primary cause of anemia in CKD is insufficient production of endogenous erythropoietin, a hormone crucial for the maturation of red blood cell precursors. Recent years have unveiled additional contributing factors, including impaired bone marrow response to erythropoietin due to uremic toxins and inflammation, reduced iron availability for erythropoiesis, heightened levels of hepcidin, shortened red blood cell lifespan, and deficiencies in vitamins like B12 or folic acid. CKD-related anemia can manifest early, even as early as CKD stages 2 and 3, per KDIGO guidelines. Hemoglobin levels decline when the estimated glomerular filtration rate (eGFR) reaches approximately 70 ml/min/1.73m² for men and 50 ml/min/1.73m² for women. Nevertheless, anemia becomes more prevalent in CKD stage 4 (even earlier among diabetic patients) and exacerbates with CKD progression. In advanced CKD stages and among those undergoing dialysis, anemia affects up to 90% of patients. Typically, CKD-associated anemia presents as normocytic and normochromic, without concomitant iron deficiency (indicated by ferritin levels above 100 ng/ml and transferrin saturation index [TSAT] exceeding 20%). When abnormal results arise in other parameters, alternative causes of anemia should be considered. Managing CKD-associated anemia revolves around administering iron and erythropoiesis-stimulating agents (ESA).

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Renal Anemia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034